MAPS

R&D Medicines > LSD/Psilocybin for Anxiety Related to Life-threatening Illness

LSD is short for d-lysergic acid diethylamide, and was discovered to be a psychedelic substance by Dr. Albert Hofmann on April 19, 1943. Psilocybin is a psychedelic compound also discovered by Hofmann which are found in psychedelic mushrooms. These mushrooms have been used for thousands of years by a variety of indigenous cultures for a variety of religious and therapeutic purposes. Both of these substances are well known for eliciting personal growth and mystical experiences in people who use them wisely.  MAPS is interested in these substances for their potential to help people with a variety of conditions. Currently we are focused on developing these drugs into prescription medicines to treat anxiety associated with life-threatening illnesses. Though there has been substantial prior research with LSD in cancer patients that demonstrated safety and some degree of efficacy, that research was conducted over 35 years ago. In order to generate data that will be accepted by today’s regulatory agencies, new protocols must meet modern drug development standards. Our research has had to start from scratch and has been designed carefully.  Our LSD and psilocybin studies will be used to guide the development of future treatment approaches.

Maps Research

Dear Readers, please do not assume that you understand anything you read on this blog.(:-)